Skip to main content

Table 2 Unadjusted biomarker concentrations at study baseline and follow up time points

From: Biomarker profiling for risk of future heart failure (HFpEF) development

Biomarker

HFpEF progressor

HFpEF Non progressor

p-value

BNP Baseline

107.7 [51.4:179.2]

39.8 [19.6:74.5]

 < 0.001

BNP Follow up

117.0 [63.9:179.0]

47.2 [25.4:79.1]

 < 0.001

Galecin-3 Baseline

15.9 [14.8:18.6]

14.9 [12.5:18.3]

0.0663

Galectin-3 Follow up

17.9 [14.8:20.0]

15.4 [12.5:18.0]

0.0090

hsTroponin I Baseline

7.7 [5.6:10.0]

5.8 [4.8:7.7]

0.0647

hsTroponin I Follow up

7.2 [5.8:10.9]

6.2 [4.5:7.6]

0.0202

sST2 Baseline

25.3 [21.3:30.5]

22.9 [20.5:29.0]

0.3711

sST2 Follow up

25.3 [22.6:29.8]

24.6 [19.6:32.3]

0.4488

IL6 Baseline

1.4 [1.0:2.1]

1.1 [0.76:1.8]

0.0731

IL6 Follow up

1.4 [1.0:1.8]

1.0 [0.79:1.9]

0.0861

  1. BNP b-type natriuretic peptide, hsTroponin I high sensitivity troponin I, sST2 soluble suppression of tumorigenicity 2, IL6 interleukin 6. Units, BNP pg/mL; Galectin-3 ng/mL; hsTroponin I pg/mL; sST2 ng/mL; IL6 pg/mL